A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma
Phase of Trial: Phase II/III
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Glycopyrrolate (Primary) ; Olodaterol/tiotropium bromide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 27 Aug 2018 Planned End Date changed from 1 Jul 2019 to 27 Sep 2019.
- 27 Aug 2018 Planned primary completion date changed from 1 Jul 2019 to 27 Sep 2019.
- 27 Jul 2018 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.